Technology transfer / Localization · GCC · Announced 28 Oct 2025
Local Content and Government Procurement Authority → Sudair Pharma
Saudi Arabia's LCGPA signed an agreement with Sudair to localise nilotinib capsules, a cancer treatment, at the Global Health Exhibition 2025 in Riyadh.
Parties: Local Content and Government Procurement Authority (LCGPA) (Saudi Arabia) → Sudair Pharma (Saudi Arabia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia — local manufacturing and knowledge transfer
- Therapeutic area
- Oncology
- Asset
- nilotinib
- Announced
- 28 Oct 2025
Our analysis
Why this matters
On 28 October 2025, at the Global Health Exhibition in Riyadh, Saudi Arabia's Local Content and Government Procurement Authority (LCGPA) signed five localisation agreements. One covered nilotinib capsules, a cancer treatment, and was signed separately with three companies: Tabuk Pharmaceuticals, a company named only as "Pharma", and Sudair (named in the source as شركة سدير).
No value was given for each agreement. The LCGPA expects the five agreements together to add more than SAR 1.2 billion to GDP and about 500 direct jobs. Single source: Al Watan. Our reading is that "Sudair" refers to Sudair Pharma; the source gives only the short name.
The full analysis is free to read with a work email on this page.
Source: Al Watan (Saudi Arabia)